Epsilon Healthcare (ASX:EPN) Beginning Cash Position: A$0.92 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Epsilon Healthcare Beginning Cash Position?

Epsilon Healthcare ASX:EPN Beginning Cash Position is A$0.92 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Epsilon Healthcare's Beginning Cash Position for the quarter that ended in Dec. 2025 was A$0.92 Mil.

Epsilon Healthcare's quarterly Beginning Cash Position declined from Dec. 2024 (A$3.23 Mil) to Jun. 2025 (A$1.57 Mil) and declined from Jun. 2025 (A$1.57 Mil) to Dec. 2025 (A$0.92 Mil).

Epsilon Healthcare's annual Beginning Cash Position declined from Dec. 2023 (A$0.81 Mil) to Dec. 2024 (A$0.34 Mil) but then increased from Dec. 2024 (A$0.34 Mil) to Dec. 2025 (A$1.57 Mil).

Epsilon Healthcare Beginning Cash Position Related Terms

Epsilon Healthcare Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Epsilon Healthcare's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epsilon Healthcare Beginning Cash Position Chart

Epsilon Healthcare Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 6.97 2.34 0.81 0.34 1.57

Epsilon Healthcare Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.34 3.23 1.57 0.92

Epsilon Healthcare Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$0.92 Mil mean?
Epsilon Healthcare (ASX:EPN) has a Beginning Cash Position of A$0.92 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Epsilon Healthcare and its competitors.
Is Epsilon Healthcare's Beginning Cash Position too high?
Epsilon Healthcare's current Beginning Cash Position is A$0.92 Mil.
How does Epsilon Healthcare's Beginning Cash Position compare to ZTS and UTHR?
Epsilon Healthcare's Beginning Cash Position of A$0.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Epsilon Healthcare and its competitors. Epsilon Healthcare's current Beginning Cash Position is A$0.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Epsilon Healthcare (ASX:EPN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 26.7% below its estimated fair value. The current Beginning Cash Position is A$0.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current Beginning Cash Position is A$0.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epsilon Healthcare Business Description

Other Exchanges HDRPF:USA
Address 5 Goodyear Street, Southport, QLD, AUS, 4215
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.